Adamis Pharmaceuticals Corp Director William C. Denby Buys 2,500 Shares (ADMP)
Adamis Pharmaceuticals Corp (NASDAQ:ADMP) Director William C. Denby purchased 2,500 shares of Adamis Pharmaceuticals Corp stock in a transaction that occurred on Tuesday, September 2nd. The shares were purchased at an average cost of $5.06 per share, with a total value of $12,650.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Shares of Adamis Pharmaceuticals Corp (NASDAQ:ADMP) traded down 4.73% during mid-day trading on Wednesday, hitting $4.83. The stock had a trading volume of 340,610 shares. Adamis Pharmaceuticals Corp has a 1-year low of $2.62 and a 1-year high of $11.90. The stock has a 50-day moving average of $3.77 and a 200-day moving average of $5.24. The company’s market cap is $50.7 million.
Separately, analysts at CRT Capital reiterated a “positive” rating on shares of Adamis Pharmaceuticals Corp in a research note on Tuesday, June 24th. They now have a $15.00 price target on the stock.
Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), formerly Cellegy Pharmaceuticals, Incoperates through its wholly owned subsidiaries Cellegy Holdings, Inc, Adamis Corporation and Biosyn, Inc Adamis Corporation has two wholly owned subsidiaries: Adamis Viral Therapies, Inc (Adamis Viral) and Adamis Laboratories, Inc (Adamis Labs).
Receive News & Ratings for Adamis Pharmaceuticals Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.